ARA-290 (cibinetide) for neuropathy: the clinical trial peptide If BPC-157 represents the strongest preclinical evidence for peptide-based nerve repair, ARA-290 represents the strongest clinical evidence
Ochs et al., 2022) within the CNS parenchyma remains to be established
This preparation is contraindicated in patients who are sensitive to cobalt and/or vitamin B12. As this product contains benzyl alcohol, it should not be used in newborns or in people who are sensitive to benzyl alcohol
Food & Drug Administration (FDA) would disagree with DSIPs designation as incredibly safe, as the peptide is included on its list of bulk drug substances with significant safety risks
Individuals suffering from malabsorption may find this particularly beneficial
Bigelow Apothecaries in New York, doesn't sell peptides in his store, which is stocked with a mix of vitamins, high-end beauty supplies and medications - all products he believes to be safe